PostEra vs Revvity

Side-by-side comparison of AI visibility scores, market position, and capabilities

Revvity leads in AI visibility (94 vs 80)
PostEra logo

PostEra

LeaderHealthcare

General

SF AI medicinal chemistry platform with $1B+ pharma partnerships; $610M Pfizer expansion Jan 2025 ($12M upfront) hitting preclinical milestones 40% faster; $26M raised competing with Schrödinger for AI small molecule and ADC drug design.

AI VisibilityBeta
Overall Score
A80
Category Rank
#107 of 1158
AI Consensus
71%
Trend
up
Per Platform
ChatGPT
75
Perplexity
81
Gemini
76

About

PostEra is a San Francisco-based AI-powered medicinal chemistry and drug discovery platform — backed with $26 million in total funding — providing pharmaceutical companies with the Proton AI platform for designing new small molecules and antibody-drug conjugates (ADCs) that accelerates the design-make-test cycle in drug discovery through machine learning models trained on medicinal chemistry synthesis rules and structure-activity relationships. PostEra has secured over $1 billion in total AI drug discovery partnerships including a $610 million collaboration expansion with Pfizer in January 2025 ($12 million upfront payment plus milestone payments and tiered royalties), and a partnership with Amgen and NIH. In the Pfizer collaboration, PostEra hit preclinical development milestones 40% faster than Pfizer anticipated, validating the AI acceleration thesis at pharmaceutical scale.

Full profile
Revvity logo

Revvity

LeaderHealthcare Tech

Life Science Tools & Diagnostics

Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.

AI VisibilityBeta
Overall Score
A94
Category Rank
#1 of 1
AI Consensus
72%
Trend
up
Per Platform
ChatGPT
92
Perplexity
99
Gemini
96

About

Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.

Full profile

AI Visibility Head-to-Head

80
Overall Score
94
#107
Category Rank
#1
71
AI Consensus
72
up
Trend
up
75
ChatGPT
92
81
Perplexity
99
76
Gemini
96
83
Claude
89
71
Grok
88

Key Details

Category
General
Life Science Tools & Diagnostics
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Revvity
Life Science Tools & Diagnostics

Integrations

Both integrate with
Only PostEra
PostEra is classified as company. Revvity is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.